APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Analysis and Forecast 2026-2032

2 January 2026193 pages

Choose your research edition.

Industry ResearchHuman Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) include Weiguang Biological, CTBB, Shanghai RAAS, Nanyue Biopharming, Hualan Bio, Sinopharm, Guangdong Shuagnlin Bio-pharmacy, Boya-Bio and Beijing Tiantan Biological Products, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19), also provides the sales of main regions and countries. Of the upcoming market potential for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) sales, projected growth trends, production technology, application and end-user industry.

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Company

Weiguang Biological

CTBB

Shanghai RAAS

Nanyue Biopharming

Hualan Bio

Sinopharm

Guangdong Shuagnlin Bio-pharmacy

Boya-Bio

Beijing Tiantan Biological Products

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Type

1.25g/25ml

10g/200ml

1g/20ml

2.5g/50ml

5g/100ml

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Application

Hospital

Clinic

Others

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 1.25g/25ml Major Manufacturers Table 3. 10g/200ml Major Manufacturers Table 4. 1g/20ml Major Manufacturers Table 5. 2.5g/50ml Major Manufacturers Table 6. 5g/100ml Major Manufacturers Table 7. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Major Manufacturers Table 9. Clinic Major Manufacturers Table 10. Others Major Manufacturers Table 11. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Trends Table 12. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Drivers Table 13. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Opportunities and Challenges Table 14. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Restraints Table 15. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Region (2021-2026) Table 19. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Region (2027-2032) Table 20. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2021-2026) & (K Units) Table 22. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2027-2032) & (K Units) Table 23. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Region (2021-2026) Table 24. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Region (2027-2032) Table 25. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Manufacturers (2021-2026) Table 29. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturers, Product Type & Application Table 33. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2021-2026) Table 40. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2027-2032) Table 41. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 43. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2027-2032) & (K Units) Table 44. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2021-2026) Table 45. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2027-2032) Table 46. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type (2021-2026) & (US$/Unit) Table 47. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type (2027-2032) & (US$/Unit) Table 48. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application (2021-2026) Table 52. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application (2027-2032) Table 53. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 55. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2027-2032) & (K Units) Table 56. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2021-2026) Table 57. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2027-2032) Table 58. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application (2021-2026) & (US$/Unit) Table 59. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application (2027-2032) & (US$/Unit) Table 60. Weiguang Biological Company Information Table 61. Weiguang Biological Business Overview Table 62. Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 64. Weiguang Biological Recent Development Table 65. CTBB Company Information Table 66. CTBB Business Overview Table 67. CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 69. CTBB Recent Development Table 70. Shanghai RAAS Company Information Table 71. Shanghai RAAS Business Overview Table 72. Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 74. Shanghai RAAS Recent Development Table 75. Nanyue Biopharming Company Information Table 76. Nanyue Biopharming Business Overview Table 77. Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 79. Nanyue Biopharming Recent Development Table 80. Hualan Bio Company Information Table 81. Hualan Bio Business Overview Table 82. Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 84. Hualan Bio Recent Development Table 85. Sinopharm Company Information Table 86. Sinopharm Business Overview Table 87. Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 89. Sinopharm Recent Development Table 90. Guangdong Shuagnlin Bio-pharmacy Company Information Table 91. Guangdong Shuagnlin Bio-pharmacy Business Overview Table 92. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 94. Guangdong Shuagnlin Bio-pharmacy Recent Development Table 95. Boya-Bio Company Information Table 96. Boya-Bio Business Overview Table 97. Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 99. Boya-Bio Recent Development Table 100. Beijing Tiantan Biological Products Company Information Table 101. Beijing Tiantan Biological Products Business Overview Table 102. Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio Table 104. Beijing Tiantan Biological Products Recent Development Table 105. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2026) & (US$ Million) Table 106. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2027-2032) & (US$ Million) Table 107. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 108. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2027-2032) & (K Units) Table 109. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Type (2021-2026) & (US$/Unit) Table 110. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Type (2027-2032) & (US$/Unit) Table 111. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2026) & (US$ Million) Table 112. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2027-2032) & (US$ Million) Table 113. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 114. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2027-2032) & (K Units) Table 115. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Application (2021-2026) & (US$/Unit) Table 116. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Application (2027-2032) & (US$/Unit) Table 117. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 119. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 120. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 121. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 122. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 123. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Country (2021-2026) & (US$/Unit) Table 124. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Country (2027-2032) & (US$/Unit) Table 125. United States Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 126. Canada Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 127. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2026) & (US$ Million) Table 128. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2027-2032) & (US$ Million) Table 129. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 130. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2027-2032) & (K Units) Table 131. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Type (2021-2026) & (US$/Unit) Table 132. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Type (2027-2032) & (US$/Unit) Table 133. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2026) & (US$ Million) Table 134. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2027-2032) & (US$ Million) Table 135. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 136. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2027-2032) & (K Units) Table 137. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Application (2021-2026) & (US$/Unit) Table 138. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Application (2027-2032) & (US$/Unit) Table 139. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 141. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 142. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 143. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 144. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 145. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Country (2021-2026) & (US$/Unit) Table 146. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Country (2027-2032) & (US$/Unit) Table 147. Germany Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 148. France Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 149. U.K. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 150. Italy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 151. Netherlands Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 152. Nordic Countries Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 153. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2026) & (US$ Million) Table 154. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2027-2032) & (US$ Million) Table 155. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 156. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2027-2032) & (K Units) Table 157. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Type (2021-2026) & (US$/Unit) Table 158. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Type (2027-2032) & (US$/Unit) Table 159. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2026) & (US$ Million) Table 160. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2027-2032) & (US$ Million) Table 161. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 162. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2027-2032) & (K Units) Table 163. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Application (2021-2026) & (US$/Unit) Table 164. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Application (2027-2032) & (US$/Unit) Table 165. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2026) & (US$ Million) Table 166. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2027-2032) & (US$ Million) Table 167. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 168. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2027-2032) & (K Units) Table 169. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Type (2021-2026) & (US$/Unit) Table 170. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Type (2027-2032) & (US$/Unit) Table 171. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2026) & (US$ Million) Table 172. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2027-2032) & (US$ Million) Table 173. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 174. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2027-2032) & (K Units) Table 175. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Application (2021-2026) & (US$/Unit) Table 176. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Application (2027-2032) & (US$/Unit) Table 177. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 178. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 179. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 180. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 181. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 182. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 183. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Country (2021-2026) & (US$/Unit) Table 184. Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Country (2027-2032) & (US$/Unit) Table 185. Japan Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 186. South Korea Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 187. India Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 188. Australia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 189. China Taiwan Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 190. Southeast Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 191. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2026) & (US$ Million) Table 192. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2027-2032) & (US$ Million) Table 193. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2026) & (K Units) Table 194. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2027-2032) & (K Units) Table 195. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Type (2021-2026) & (US$/Unit) Table 196. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Type (2027-2032) & (US$/Unit) Table 197. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2026) & (US$ Million) Table 198. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2027-2032) & (US$ Million) Table 199. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2026) & (K Units) Table 200. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2027-2032) & (K Units) Table 201. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Application (2021-2026) & (US$/Unit) Table 202. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Application (2027-2032) & (US$/Unit) Table 203. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 204. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 205. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 206. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 207. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021-2026) & (K Units) Table 208. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2027-2032) & (K Units) Table 209. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Country (2021-2026) & (US$/Unit) Table 210. SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Country (2027-2032) & (US$/Unit) Table 211. Brazil Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 212. Argentina Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 213. Chile Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 214. Colombia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 215. Peru Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 216. Saudi Arabia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 217. Israel Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 218. UAE Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 219. Turkey Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 220. Iran Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 221. Egypt Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Table 222. Key Raw Materials Table 223. Raw Materials Key Suppliers Table 224. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Distributors List Table 225. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Customers List Table 226. Research Programs/Design for This Report Table 227. Authors List of This Report Table 228. Secondary Sources Table 229. Primary Sources List of Figures Figure 1. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Image Figure 2. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Share 2021 VS 2025 VS 2032 Figure 4. 1.25g/25ml Image Figure 5. 10g/200ml Image Figure 6. 1g/20ml Image Figure 7. 2.5g/50ml Image Figure 8. 5g/100ml Image Figure 9. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Image Figure 12. Clinic Image Figure 13. Others Image Figure 14. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (2021-2032) & (US$ Million) Figure 16. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Region (2021-2032) Figure 19. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (2021-2032) & (K Units) Figure 20. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales YoY (2021-2032) & (K Units) Figure 23. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales YoY (2021-2032) & (K Units) Figure 24. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales YoY (2021-2032) & (K Units) Figure 27. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2021-2032) Figure 33. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2021-2032) Figure 36. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application (2021-2032) Figure 39. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2021-2032) Figure 42. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Type (2021-2032) Figure 43. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Share by Type (2021-2032) Figure 44. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Application (2021-2032) Figure 45. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Share by Application (2021-2032) Figure 46. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Country (2021-2032) Figure 47. North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Share by Country (2021-2032) Figure 48. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Share by Type (2021-2032) Figure 49. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Share by Type (2021-2032) F

Scope & coverage.

Types
  • 1.25g/25ml
  • 10g/200ml
  • 1g/20ml
  • 2.5g/50ml
  • 5g/100ml
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Weiguang Biological
  • CTBB
  • Shanghai RAAS
  • Nanyue Biopharming
  • Hualan Bio
  • Sinopharm
  • Guangdong Shuagnlin Bio-pharmacy
  • Boya-Bio
  • Beijing Tiantan Biological Products

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Type
  3. 1.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 1.25g/25ml
  5. 1.2.3 10g/200ml
  6. 1.2.4 1g/20ml
  7. 1.2.5 2.5g/50ml
  8. 1.2.6 5g/100ml
  9. 1.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Application
  10. 1.3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Clinic
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Dynamics
  1. 2.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Trends
  2. 2.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Drivers
  3. 2.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Opportunities and Challenges
  4. 2.4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region
  3. 3.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region (2021-2026)
  5. 3.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region (2027-2032)
  6. 3.2.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region
  9. 3.4.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2021-2026)
  11. 3.4.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2027-2032)
  12. 3.4.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Manufacturers
  2. 4.1.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Manufacturers
  6. 4.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturers, Product Type & Application
  13. 4.7 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market CR5 and HHI
  16. 4.8.2 2025 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Tier 1, Tier 2, and Tier 3
5 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Type
  1. 5.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type
  2. 5.1.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type
  6. 5.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type
6 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market by Application
  1. 6.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application
  2. 6.1.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application
  6. 6.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application
7 Company Profiles
  1. 7.1 Weiguang Biological
  2. 7.1.1 Weiguang Biological Company Information
  3. 7.1.2 Weiguang Biological Business Overview
  4. 7.1.3 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  6. 7.1.5 Weiguang Biological Recent Developments
  7. 7.2 CTBB
  8. 7.2.1 CTBB Company Information
  9. 7.2.2 CTBB Business Overview
  10. 7.2.3 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  12. 7.2.5 CTBB Recent Developments
  13. 7.3 Shanghai RAAS
  14. 7.3.1 Shanghai RAAS Company Information
  15. 7.3.2 Shanghai RAAS Business Overview
  16. 7.3.3 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  18. 7.3.5 Shanghai RAAS Recent Developments
  19. 7.4 Nanyue Biopharming
  20. 7.4.1 Nanyue Biopharming Company Information
  21. 7.4.2 Nanyue Biopharming Business Overview
  22. 7.4.3 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  24. 7.4.5 Nanyue Biopharming Recent Developments
  25. 7.5 Hualan Bio
  26. 7.5.1 Hualan Bio Company Information
  27. 7.5.2 Hualan Bio Business Overview
  28. 7.5.3 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  30. 7.5.5 Hualan Bio Recent Developments
  31. 7.6 Sinopharm
  32. 7.6.1 Sinopharm Company Information
  33. 7.6.2 Sinopharm Business Overview
  34. 7.6.3 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  36. 7.6.5 Sinopharm Recent Developments
  37. 7.7 Guangdong Shuagnlin Bio-pharmacy
  38. 7.7.1 Guangdong Shuagnlin Bio-pharmacy Company Information
  39. 7.7.2 Guangdong Shuagnlin Bio-pharmacy Business Overview
  40. 7.7.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  42. 7.7.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
  43. 7.8 Boya-Bio
  44. 7.8.1 Boya-Bio Company Information
  45. 7.8.2 Boya-Bio Business Overview
  46. 7.8.3 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  48. 7.8.5 Boya-Bio Recent Developments
  49. 7.9 Beijing Tiantan Biological Products
  50. 7.9.1 Beijing Tiantan Biological Products Company Information
  51. 7.9.2 Beijing Tiantan Biological Products Business Overview
  52. 7.9.3 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
  54. 7.9.5 Beijing Tiantan Biological Products Recent Developments
8 North America
  1. 8.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Type
  2. 8.1.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2032)
  3. 8.1.2 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2032)
  4. 8.1.3 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type (2021-2032)
  5. 8.2 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Application
  6. 8.2.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2032)
  7. 8.2.2 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2032)
  8. 8.2.3 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application (2021-2032)
  9. 8.3 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country
  10. 8.3.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Type
  2. 9.1.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2032)
  4. 9.1.3 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type (2021-2032)
  5. 9.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Application
  6. 9.2.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2032)
  8. 9.2.3 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application (2021-2032)
  9. 9.3 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country
  10. 9.3.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Type
  2. 10.1.1 China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2032)
  3. 10.1.2 China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2032)
  4. 10.1.3 China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type (2021-2032)
  5. 10.2 China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Application
  6. 10.2.1 China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2032)
  7. 10.2.2 China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2032)
  8. 10.2.3 China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Type
  2. 11.1.1 Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2032)
  4. 11.1.3 Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type (2021-2032)
  5. 11.2 Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Application
  6. 11.2.1 Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2032)
  8. 11.2.3 Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application (2021-2032)
  9. 11.3 Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country
  10. 11.3.1 Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Type
  2. 12.1.1 SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type (2021-2032)
  5. 12.2 SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Application
  6. 12.2.1 SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application (2021-2032)
  9. 12.3 SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country
  10. 12.3.1 SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Value Chain Analysis
  2. 13.1.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Production Mode & Process
  6. 13.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Distributors
  9. 13.2.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst